PSX1001 | PSX1002 | PSX2000 Series | Partners

In addition to its respiratory internal pipeline, Prosonix has established multiple co-development partnerships with pharmaceutical companies, through which its particle engineering technology and approach has been validated.

Furthermore, niche opportunities also exist for several novel orally and parentally delivered products addressing wider disease indications, in particular those with challenging primary and secondary manufacturing processes or those exhibiting poor aqueous solubility where particle size and morphology control is a very important consideration.

Prosonix welcomes enquiries from all parties interested in licensing and co-development opportunities.

Click here to view the Business Development contact form.